Please ensure Javascript is enabled for purposes of website accessibility

Why Sorrento Therapeutics Stock Surged Today

By Joe Tenebruso - Updated Feb 1, 2021 at 5:17PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech announced promising results for its experimental coronavirus therapy.

What happened

Shares of Sorrento Therapeutics (SRNE 6.94%) climbed 15.6% on Monday, after the biopharmaceutical company released encouraging data from its phase 1b study of its COVID-19 treatment candidate, COVI-MSC.  

So what 

COVI-MSC is a stem cell therapy intended for patients with COVID-19-induced acute respiratory distress. Sorrento said on Jan. 26 that the first three people who received COVI-MSC were discharged from the hospital within a week. 

On Sunday, the biotech said a fourth patient, who had required mechanical ventilation because of deteriorating respiratory function, saw his condition quickly improve and was able to be discharged from the hospital the evening after his third infusion of COVI-MSC. 

A person is pointing to an upwardly sloping digital stock chart.

Sorrento Therapeutics' stock jumped on Monday. Image source: Getty Images.

Better still, no adverse safety events were reported during the study.

"It brings us great joy each time one of our treatments helps to save a life, after all, that is what we at Sorrento work toward each and every day to save one life at a time," Sorrento CEO Dr. Henry Ji said in a press release. 

Now what

Analysts have praised Sorrento's pipeline of diagnostic tests and therapies that, if approved, could generate more than $2 billion in near-term sales, according to Alliance Global analyst James Molloy. Meanwhile, B. Riley Securities analyst Mayank Mamtani believes Sorrento's stock price could rise roughly 78% to $26, thanks to its diversified portfolio of projects. 

"With three shots on goal -- therapeutic antibodies for a variety of diseases, including COVID-19; non-opioid pain therapies across multiple indications; and a very early stage immunotherapy effort -- SRNE is well-positioned for success," Mamtani said on Friday. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Sorrento Therapeutics, Inc. Stock Quote
Sorrento Therapeutics, Inc.
SRNE
$1.54 (6.94%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
332%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.